“We are now a step closer to filing a pre-IND application for HIVCide™ with the US FDA,” said Eugene Seymour, MD, MPH, CEO of the Company.
A
NanoViricides Reports that Antiviral Efficacy was Demonstrated Against Two Different HIV-1 Isolates in Cell Culture Studies, Corroborating Previous Findings in Animal Studies
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.
This in vitro or cell culture study validated the in vivo anti-HIV activity of the nanoviricides® as determined in a SCID/hu Thy/Liv mouse model by KARD Scientific, a contract research organization, and previously reported by the Company.
Significantly, a subset of the anti-HIV nanoviricides tested in cell culture models at Southern Research had very similar activity against two distinctly different isolates of HIV-1, viz. Ba-L and IIIB. The Company had designed the ligands using reported gp120 structures of several HIV-1 strains.
The HIV-1 isolate Ba-L was the same as that employed in the Company’s previously reported animal model studies. This virus binds and infects cells expressing the human receptor CCR5 in addition to the well known receptor CD4. In contrast, HIV-1 IIIB is a CXCR4-tropic virus that infects cells expressing the human receptor CXCR4 in addition to the receptor CD4. The same viral gp120 or SU glycoprotein is involved in binding to both co-receptors, viz. CD4 and either CCR5 or CXCR4. HIV that binds to CD4 and to at least one other co-receptor, such as CXCR4 or CCR5, results in productive infection leading to disease, and eventually AIDS.
It has been a formidable challenge for researchers in the field to develop an anti-HIV drug that works against all subtypes and strains. Several anti-HIV drugs and drug candidates have demonstrated significant activity against only one of these various HIV-1 subtypes. In addition, HIV mutates, changing its genome and protein structure during an active infection. Mutants resistant to the patients’ treatment drugs can develop and proliferate, leading to failure of therapy, including the HAART regimen.
“We believe that our strategy of designing ligands that are close mimics of the invariant binding site on CD4 has resulted in nanoviricides that are active against multiple HIV-1 subtypes,” said Anil R. Diwan, PhD, President of the Company, adding, “The results of the Southern Research study suggest that mutations in HIV-1 may be unlikely to result in significant resistance to an anti-HIV nanoviricide.”
The Company had provided Southern Research with a panel of seventeen substances, including active and inactive substances. The Southern Research study was performed three different times on the same set of materials with substantially consistent results. The results confirmed that the previously demonstrated in vivo anti-HIV activity of certain nanoviricides was correlated with their in vitro anti-HIV activity.
The Company has previously reported that several of its nanoviricide drug candidates were more than 25 times (2,500%) superior to a three-drug HAART cocktail in a standard SCID-hu Thy/Liv mouse model study of HIV-I infection. In particular, treatment with only 150 mg/kg nanoviricides, as opposed to 4,200 mg/kg HAART drug cocktail (i.e. 28 times greater total dosage of HAART cocktail) resulted in viral load decrease that was equal to or better than HAART, and increased double-positive CD4+/CD8+ T cell counts that were equal to or better than HAART. The nanoviricides were equal or superior to the HAART cocktail in all parameters evaluated. Significantly, the nanoviricide treatment was given only during the first week in this six-week anti-HIV study, whereas HAART treatment was continued daily.
“We are now a step closer to filing a pre-IND application for HIVCide™ with the US FDA,” said Eugene Seymour, MD, MPH, CEO of the Company.
9 comments:
How many additional steps are needed?
It doesn't matter, each step will add millions in market cap and again, this is just one of a half-dozen or more anti-virals. The UCSF animal studies on Dengue will be huge, that's up next so watch for it.
All current company cash is required for pre-IND. Then another 10-15Million for IND and 5-10M to support the IND. The company will have to raise funds somehow. Given its history, the company will sell engage in somewhat toxic financing and enrich themselves.
http://www.nationalterroralert.com/updates/2010/05/23/dengue-fever-hits-key-west-florida/
The post about company cash and raising funds sounds like something meaningful that deserves an audience.... but the poster has hit and run,leaving the point incomplete.
Maybe you could come back and further explain what you mean and offer Both the positive side and negative side of the issue as pertains to what could happen for NNVC.
No arguement is complete without a fair description of both sides of the issue.
Your comments sounded negative about NNVC. I'd like to hear a more thorough arguement that deserves attention.
I like the sound of Allan's
arguements For NNVC,and Patrick Cox's arguements For NNVC.
I still havent heard anything to convince me to sell and give it up.
I was concerned and alarmed last fall when NNVC was steadily being manipulated down to .49 cents.
I said "WTF".
Is that what you mean by the issue of a company needing to 'raise cash' ? that we will see another one of those irrational sell downs ? back to .....60 cents or something?
Many additional steps are needed: INDA filing, Stage I tests, Stage II tests, Stage III tests... just to name a few.
And the company doesn't have the money to pull them all off. If you read the SEC filings, they say they might have enough money to get through the INDA phase.
Doubling or tripling the shares to about 500 million outstanding seems to be the only way to go.
I have been reading the concerns about future refinancing and I believe it has already been reflected in the charts with the stock price plummeting from $2.64 to $1.46.
Currently,technically speaking, NNVC is beginning to build a nice chart.If NNVC closes above $1.75 on the week It will have a Bullish Engulfing candlestick on the weekly chart-a strong signal. Get ready for a trending move upward through the last high of $2.64.
If you are not in get in. If you are long and not fully invested add to your position
Good luck to all Longs.
H.
I can't see how TA can be used with this stock. One week it has "X" number of shares in the float, a few weeks later it has a million more shares.
How can you use price and volume to chart the stock's future when the volume depends on shares issued in a given week, and the market cap changes constantly?
Allan, do you have any insights on TA for stocks with constantly increasing float numbers?
I believe you mean shares traded not "number of shares in float" nor "shares issued".
Trading volumes always vary on every stock and so does the market price.NNVC is not unique to this.
Allan's key point is that one should be in this stock at all times so as not to miss a big announcement(eg.positive results from a Phase III test, FDA approval, or even an offer to buy out the company). I agree , and so one may hold a core block and trade over and above the core number of shares.
Post a Comment